TRVI
Trevi Therapeutics, Inc. [TRVI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
TRVI Stock Summary
In the News
TRVI Financial details
Company Rating
-
Market Cap
201.36M
Income
-29.07M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
25
Optionable
No
Shortable
Yes
Earnings
09 May 2024
P/E
-5.01
Forward P/E
-
PEG
1.44
P/S
-
P/B
1.5
P/C
-
P/FCF
-2.7
Quick Ratio
17.18
Current Ratio
18.16
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.29
EPS next Y
-
EPS next Q
-
EPS this Y
-35.56%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
1.42%
-
-
-
-
SMA20
-
SMA50
-15.38%
SMA100
22.22%
Inst Own
-
Inst Trans
-
ROA
-28%
ROE
-27%
ROC
-0.35%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.97-4.0
52W High
-
52W Low
-
RSI
54
Rel Volume
2.6
Avg Volume
307.78K
Volume
800.44K
Perf Week
9.71%
Perf Month
1.06%
Perf Quarter
59.58%
Perf Half Y
56.73%
-
-
-
-
Beta
0.867
-
-
Volatility
0.45%, 0.44%
Prev Close
2.79%
Price
11.41
Change
5.5%
Company Profile
- Volume Average 307.78K
- Market Capitalization 201.36M
- Employee 25
- CEO Ms. Jennifer L. Good
- Headquarters New Haven,CT,US
- IPO Date 2019-05-07
-
Website
https://www.trevitherapeutics.com 
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
